Dallas, TX: ReportsandReports announce it will carry Novartis AG: PharmaVitae Profile Market Research Report in its Store. Browse complete Novartis AG: PharmaVitae Profile Report Introduction This analysis examines the historical and forecast performance for Novartis in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. Reasons to Purchase Table of Content ABOUT DATAMONITOR HEALTHCARE About the PharmaVitae team Chapter 1 About this profile PharmaVitae Explorer database Chapter structure Executive summary Quarterly update Company introduction Company sales Company financials Key products Data sourcing Sales data Analyst consensus Chapter 2 Executive summary Key findings Prescription pharmaceutical sales and growth rate performance, 2003-15 Financial performance, 2003-15 Novartis: PharmaVitae forecasts at a glance Strategic insight Novartis is forecast to deliver strongest organic growth within Big Pharma 2009-15 Diversified prescription pharma offering integral to sales growth performance Exposure to generic competition will blunt branded pharmaceutical sales growth Evolution of vaccine offering will drive steady revenue growth Sandoz poised to exploit diverse segments of global generics market Further diversification to be driven by Alcon acquisition SWOT analysis Strengths Weaknesses Opportunities Threats Table of Contents Table of figures Chapter 3 Quarterly update Latest quarterly sales Latest comment Q2 2010 Novartis: blockbuster revenues beckon for multiple sclerosis pill Lucentis shows potential in diabetic macular edema AAN 2010: spotlight shines on Novartis’ and Merck KGaA’s oral MS candidates Q1 2010 Novartis: Debiopharm deal strengthens hepatitis C pipeline Novartis: Fanapt marks weak return to competitive antipsychotics market Novartis eyes Alcon merger Q4 2009 ASH 2009: Novartis looks to position Tasigna as an alternative to Gleevec in CML Q2 2009 Novartis: Afinitor boasts considerable commercial potential Q1 2009 Novartis: Extavia launch provides foothold in MS market Latest prescription pharma product news Q2 2010 Q1 2010 Q4 2009 Q3 2009 Q2 2009 Q1 2009 Latest corporate news Q2 2010 Q1 2010 Q4 2009 Q3 2009 Q2 2009 Q1 2009 Chapter 4 Company introduction Key findings Background Key corporate developments M&A history Push into generics market Sandoz Movement into vaccines/diagnostics Chiron Alcon deal demonstrates further diversification One eye on Alcon: a strong fit with Novartis Ophthalmics Recent M&A in branded prescription segment Chapter 5 Company sales Key findings Prescription pharmaceutical sales and growth rate analysis, 2003-15 Product analysis Product analysis, 2003-09 Product analysis, 2009-15 Product analysis, 2009-15 Therapy area analysis Geographic analysis Launch/core/expiry analysis Explanation of launch/core/expiry analysis Launch analysis, 2009-15 Core analysis, 2009-15 Expiry analysis, 2009-15 Generics analysis, 2009-15 Launch/core/expiry configuration, 2009-15 Molecule type analysis Externalization analysis Chapter 6 Company financials Key findings Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003-09 Operating costs and profit analysis Operating costs and profit analysis, 2003-09 Operating cost ratio and profit margin analysis, 2003-09 Operating cost ratio and profit margin analysis, 2009-15 Operating costs and profit analysis, 2009-15 Chapter 7 Key products Overview Glivec/Gleevec Summary Sales forecast Gilenia Summary Sales forecast QMF149 Summary Sales forecast QVA149 Summary Sales forecast Tasigna Summary Sales forecast Diovan/Co-Diovan Summary Sales forecast Co-Diovan Summary Sales forecast Zometa (includes Aclasta/Reclast) Summary Sales forecast Femara Summary Sales forecast Sandostatin Summary Sales forecast Chapter 8 Appendix References Abbreviations Exchange rates About Datamonitor About Datamonitor Healthcare Datamonitor consulting Disclaimer Browse complete Novartis AG: PharmaVitae Profile Report Browse all Healthcare Market Research Reports Browse all Datamonitor Market Research Reports RSS Browse all Latest Report Related Reports: Novartis AG-Detailed Product Pipeline Novartis AG-Deals & Alliances Report Novartis AG-Therapeutic Competitors About Us: Contact:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
Posted by
Unknown
on
